knowledge -WSS

knowledge

author：entertainment 2025-09-27 10:32:47 Page View：2296

Patient treated with Impella in the heart. -- health tech coverage from STAT — Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. Business Wire

The Food and Drug Administration is following through on its promise to regulate more health software tools, starting with a public reprimand of Johnson & Johnson’s heart pump company, Abiomed.

Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. The FDA published a warning letter on Wednesday telling the company it should have submitted its software for approval before putting it on the market. The agency also took issue with Abiomed’s failure to report various problems with its heart pumps.

The letter comes a year after the Food and Drug Administration announced its intention to regulate more health software tools, sending the industry into an uproar.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicaid rebukes states for mistakenly disenrolling children
Next article： Cancer drug shortages should be causing more outrage

explore

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

How to fix cancer clinical trials' diversity problem

Clockwisefromtopleft:STAT'sNicholasSt.Fleur(moderator);JudySewards,headofclinicaltrialexperienceatPf

Hepatitis C has a cure — but many Americans still lack access to it

AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

How generative AI is inspiring dreams of a health data revolution

MollyFergusonforSTATTheworld’slargesttechnologycompaniesareracingtobuildgenerativeAIintoeverycornero